About
Specially created for HCPs practicing in the United States, this channel focuses on a variety of products from Novo Nordisk. Keep watching to find out more about Novo Nordisk treatments, including Fiasp® (insulin aspart injection) 100 U/mL; Tresiba® (insulin degludec) injection 100 Units/mL, 200 Units/mL; Ozempic® (semaglutide) injection 0.5 mg 1 mg, or 2 mg; and RYBELSUS® (semaglutide) tablets 7 mg or 14 mg. Novo Nordisk has been driving innovation and change in health care for almost 100 years.
Subscribe to stay up to date on videos for HCPs about Novo Nordisk treatments.
Fiasp®, Ozempic®, RYBELSUS®, and Tresiba® are registered trademarks of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2022 Novo Nordisk All rights reserved. US22OZM00829 August 2022
Specially created for HCPs practicing in the United States, this channel focuses on a variety of products from Novo Nordisk. Keep watching to find out more about Novo Nordisk treatments, including Fiasp® (insulin aspart injection) 100 U/mL; Tresiba® (insulin degludec) injection 100 Units/mL, 200 Units/mL; Ozempic® (semaglutide) injection 0.5 mg 1 mg, or 2 mg; and RYBELSUS® (semaglutide) tablets 7 mg or 14 mg. Novo Nordisk has been driving innovation and change in health care for almost 100 years.
Subscribe to stay up to date on videos for HCPs about Novo Nordisk treatments.
Fiasp®, Ozempic®, RYBELSUS®, and Tresiba® are registered trademarks of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2022 Novo Nordisk All rights reserved. US22OZM00829 August 2022